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ABSTRACT
Estrogen receptor-positive breast cancer is subdivided into subtypes LuminalA 
and LuminalB, based on different expression patterns. MicroRNA-190b has been 
reported to be up-regulated in estrogen receptor-positive breast cancers. In this study 
we aimed to investigate the role of CpG promoter methylation in regulating miR-190b 
expression and its impact on clinical presentation and prognosis. DNA methylation 
analysis for the promotor of microRNA-190b was performed by pyrosequencing 549 
primary breast tumors, of which 62 were carriers of the BRCA2999del5 founder mutation, 
71 proximal normal breast samples and 16 breast derived cell lines. MicroRNA-190b 
expression was analysed in 67 primary breast tumors, 14 paired normal breast 
samples and 16 breast derived cell lines. Tissue microarrays (TMAs) were available 
for ER (n = 436), PR (n = 436), HER-2 (N = 258) and Ki67 (n = 248). MiR-190b 
had reduced promoter methylation in estrogen receptor-positive breast cancers 
(P = 1.02e–12, Median values: ER+ 24.3, ER– 38.26) and miR-190b’s expression 
was up-regulated in a correlative manner (P = 1.83e–06, Spearman’s rho –0.62). 
Through breast cancer specific survival analysis, we demonstrated that LuminalA 
patients exhibiting miR-190b hypo-methylation had better survival than other patients 
(P = 0.034, HR = 0.29, 95% CI 0.09-0.91). We, furthermore, demonstrated that 
miR-190b hypo-methylation occurs less frequently in ER+ tumors from BRCA2999del5 
mutation carriers than in non-mutated individuals (P = 0.038, Χ2 = 4.32, n = 335). Our 
results suggest that upregulation of miR-190b may occur through loss of promoter 
DNA methylation during the development of estrogen-receptor (ER) positive breast 
cancers, and that miR-190b hypo-methylation leads to increased breast cancer specific 
survival within the LuminalA- subtype but not LuminalB.
INTRODUCTION
Breast cancer is a complex, heterogeneous 
disease with at least five subtypes defined on the basis 
of genome-wide expression patterns [1–3]. These 
subtypes are thought to emerge through distinct tumor 
evolutionary paths and due to their diverse clinical 
outcome, patient prognosis is highly dependent on tumor 
subtype [4].
Estrogen receptor-positive (ER+) breast cancer 
is the most common form of breast cancer diagnosed 
representing approximately 70% of total incidences, 
and is rapidly becoming the most commonly diagnosed 
malignancy worldwide [5–7]. ER+ breast cancers, which 
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are classified as luminal subtypes LuminalA (LumA) and 
LuminalB (LumB), are most commonly treated using 
agents inhibiting the estrogen receptor or hormone levels 
[8, 9]. These cancers have fairly good prognosis, though 
a subset of patients respond poorly to treatment. This is 
particularly relevant for LumB type breast cancers, which 
are diagnosed in younger patients, have higher tumor-
proliferation rates and have worse prognosis compared 
to LumA patients [5, 10, 11]. Although LumA and LumB 
breast cancers are in general classified by defined markers, 
their full biological distinction regarding treatment remains 
poorly understood. Recent studies have shown that LumA 
and LumB breast cancers have several seperate features, 
and that the growth of these tumors is driven by different 
oncogenic mechanisms [10]. To distinguish between the 
two cancer groups is thus important for clinical practice 
[5]. It is necessary to fully study the Luminal subtypes for 
better understanding of the oncogenic mechanisms driving 
these cancers and improving patient outcomes.
The Icelandic BRCA999del5 founder mutation 
(c.771_775del5) has a prevalence of approximately 
6–7% in Icelandic female breast cancer patients. It is a 
pathogenic mutation, associated with an increased risk 
of breast-, ovarian- and other cancers. Patients with this 
mutation have been reported to have poorer prognosis than 
non-carriers, although age of onset and disease severity 
differs between individuals [12–14].
MicroRNAs (miRNA) are small non-coding RNA 
molecules with an important role in post-transcriptional 
gene silencing via sequence-specific interaction with 
the 3’UTR of mRNA. MiRNAs are important for fine 
tuning gene translation and their expression is often 
tissue specific [15], they can influence multiple genes 
simultaneously and have widespread phenotypic impact 
[16, 17].
Abnormal miRNA expression has been observed 
in cancer and multiple studies have shown that miRNA 
expression abnormalities are causatively linked to 
carcinogensis [18–20]. MiR-190b has been reported to be 
up-regulated in ER+ breast cancers [21]. However, little 
is known about the mechanism underlying miR-190b 
up-regulation or its impact on clinical presentation and 
prognosis.
In this study, we show that miR-190b promoter 
methylation loss in tumors is strongly associated with 
miR-190b over-expression and that breast cancer specific 
survival is better in individuals with hypo-methylated 
breast tumors of subtype LumA.
RESULTS
MiR-190b expression in breast derived cell lines
MiR-190b has been shown to be up-regulated in ER+ 
breast cancers, however, the mechanisms behind this up-
regulation is unknown. Therefore, we analysed miR-190b‘s 
expression and methylation status in breast derived cell lines 
(n = 16). ER+ cell lines displayed overall higher miR-190b 
expression compared to ER– cell lines (Wilcoxon rank sum 
test P = 0.011, Median values ER+ 0.025, ER– 0) (Figure 
1A). We pyrosequenced the first CpG upstream from miR-
190b‘s genomic sequence (Supplementary Figure 1) in the 
same set of 16 cell lines and found that ER+ cell lines were 
significantly less methylated comparing to ER– cell lines. 
(Wilcoxon rank sum test, P = 0.003, Median values ER+ 
3.02, ER– 38.71) (Figure 1B). MiR-190b methylation and 
expression were also significantly correlated (Spearman’s 
rho = –0.68, P = 0.004) (Supplementary Figure 2). 
Following our findings, we proceeded to investigate miR-
190b‘s expression and methylation status within patient 
derived breast tumor samples.
MiR-190b expression in ER+ and ER– breast 
cancer tumors
MiR-190b expression was measured in breast 
tumors (n = 62) and normal breast tissue samples adjacent 
to breast tumor sites (n = 15). The breast tumor samples 
showed overall higher levels of miR-190b expression 
compared to normal breast tissue (Wilcoxon rank sum 
test P = 2.18e–05, Median values Tumors 0.054, Normal 
Tissue 0.003) (Figure 2A). Paired samples of normal 
and tumor tissue were available from 13 individuals of 
the cohort. Overall pairwised miR-190b expression in 
tumors was significantly higher compared to normal tissue 
(Wilcoxon signed rank test, P = 0.003, Median values 
Tumors 0.052, Normal 0.003) (Figure 2C).
While investigating miR-190b expression by ER 
tumor status, we observed both ER+ and ER– tumors to 
over-express miR-190b comparing to normal breast tissue. 
ER+ tumors also significantly over-express miR-190b 
compared to ER– tumors (Kruskal–Wallis, P = 9.13e–07 
followed by Dunn‘s multiple comparison, Median values 
ER+ 0.086, ER– 0.01) (Figure 2B). Differences in miR-
190b expression between ER– tumors and normal tissue 
was not statistically significant in pairwised testing while 
it was statistically significant for ER+ tumors (Figure 2D). 
Following the confirmation that ER+ breast tumors over-
express miR-190b, we proceeded to investigate whether 
there was a distinction in over-expression between breast 
cancer subtypes.
MiR-190b expression in LumA vs LumB
We observed a significant increase in expression 
within the subtypes defined as ER+, namely LumA and 
LumB, compared to the ER– subtypes Basal-like and 
5NP (Kruskal–Wallis, P = 1.0e–04 followed by Dunn‘s 
multiple comparison, Median values LumA 0.14, LumB 
0.059, Basal-like 0.02, 5NP 01.01). We also observed that 
LumA breast cancers significantly express higher levels 
of miR-190b comparing to LumB. There was no evident 
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difference in expression within ER– subtypes (Basal-
like & 5NP) (Figure 3). Due to unavailability of tumor 
RNA samples from individuals diagnosed with the HER2 
subtypes, a comparison with this particular subtype could 
not be implemented. Following our observations that 
there is a distinction in miR-190b expression within ER+ 
breast cancer subtypes, we investigated whether there is 
a difference in miR-190b promoter methylation based on 
ER status and whether there is a further division within 
breast cancer subtypes.
MiR-190b methylation status in breast tumors
We pyrosequenced DNA from breast tumors 
(n = 514) and normal tissue samples (n = 72). Tumors 
were significantly less methylated comparing to normal 
tissue (Wilcoxon rank sum test, P = 1.18e–04, Median 
values Tumors 27.71, Normal tissue 35.24) (Figure 4A). 
Significant differences were observed between 43 paired 
tumor and normal tissue samples (Wilcoxon signed rank 
test, P = 0.046, Median values, Tumor 24.04, Normal 
36.29) (Supplementary Figure 3A).
From paired RNA and DNA from individual tissue 
samples (n = 63) we observed that miR-190b‘s methylation 
status is negatively-correlated to its expression in tumors 
(Spearman’s rho = –0.62, P = 1.83e–06) (Figure 4C).
ER+ tumors were significantly less methylated 
comparing to normal tissue (Wilcoxon signed rank test, 
P = 9.70e–10, Median values ER+ 24.25, Normal Tissue 
35.24/ Wilcoxon rank sum, P = 0.006, Median values ER+ 
30.45, ER– 36.19) (Figure 4B and Supplementary Figure 
3B). Methylation in ER– tumors was equivalent to normal 
tissue (Wilcoxon signed rank test, P = 0.067, Median 
values ER– tumors 38.26, Overall Normal tissue 35.24, 
Wilcoxon rank sum, P = 0.48, Median values ER–36.19, 
Normal 35.24) (Figure 4B and Supplementary Figure 3B). 
Following these observations, we looked into miR-190b‘s 
methylation status according to subtype.
Figure 1: MiR-190b expression and methylation status in breast derived cell lines. (A, left panel) MiR-190b expression is 
higher in ER+ breast cancer cell lines (n = 7) compared to ER– breast cancer cell lines (n = 9) (Wilcoxon rank sum test P = 0.011). Right 
panel- MiR-190b expression in breast cancer cell lines. (B, left panel) MiR-190b methylation is lower in ER+ (n = 7) compared to ER– cell 
lines (n = 9) (Wilcoxon rank sum test, P = 0.003). (Right panel) MiR-190b methylation in breast cancer cell lines.
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MiR-190b methylation status in breast cancer 
subtypes LumA and LumB
We observed that the ER+ subtypes LumA and 
LumB are significantly less methylated comparing to the 
ER– breast cancer subtypes Basal-like, HER2 and 5NP 
(Kruskal–Wallis test, P = 1.19e–05 followed by Dunn‘s 
multiple comparison, Median values LumA 25.10, LumB 
25.82, Basal-like 28.41, Her2 43.20, 5NP 34.71) (Figure 
5).We did not observe any significant differences in 
methylation status within subtypes of the same ER status, 
indicating that decreased methylation occurs in both the 
ER+ subtypes, LumA and LumB, in a similar manner 
(Figure 5). These findings strongly support our hypothesis 
that ER+ breast cancers over-express miR-190b via a 
reduction in promoter methylation. We subsequently 
sought to understand whether our findings are relevant 
with respect to clinical parameters.
MiR-190b promoter methylation in association 
with clinical parameters
Table 1 summarizes the clinical and pathological 
characteristics of our cohort. We define hypo-methylation 
of miR-190b below (or equal to) 20% methylation on 
the basis of the 1st quartile of the distribution in tumor 
samples. MiR-190b hypo-methylation was not found to be 
significantly prevalent with any clinical parameters other 
than ER status where roughly 87% of miR-190b hypo-
methylated tumors were ER+ (Supplementary Table 2).
MiR-190b and BRCA2999del5
The patients in our cohort had previously been 
screened for the Icelandic BRCA2999del5 founder mutation 
and BRCA2 allele proportions within mutation carriers, 
enabling us to analyse these factors with regard to 
miR-190b methylation. When analysing BRCA2 allele 
proportions we found correlation between BRCA2 
loss of heterozygosity (LOH) and decreased miR-190b 
methylation in BRCA2999del5 tumors. (Multivariate linear 
regression corrected for ER status, age at diagnosis and 
year of diagnosis, P = 0.008, R2 = 0.45, N = 28) (Figure 6). 
Only four tumors derived from carriers were miR-190b 
hypo-methylated. Looking into miR-190b hypo-
methylation with regard to overall BRCA2999del5 mutation 
status in ER+ patients, we found that miR-190b hypo-
methylation events are significantly fewer in ER+ tumors 
arising in BRCA2999del5 mutation carriers compared with 
sporadically arising ER+ tumors (Table 2).
Figure 2: MiR-190b expression in our cohort. (A) Overall miR-190b expression is higher in tumor samples (n = 62) compared to 
normal breast tissue (n = 15) (Wilcoxon rank sum test P = 2.18e–05). (B) ER+ breast cancers (n = 30) significantly over-express miR-
190b comparing to ER– (n = 13) and normal tissue (n = 15) (Kruskal–Wallis, P = 9.13e–07 with Dunn‘s multiple comparison). *< 0.05, 
**< 0.001, ***< 0.0001). (C) Overall pairwise miR-190b expression is higher in tumor samples compared to normal breast tissue (n = 13) 
(Wilcoxon signed rank test, P = 0.003). (D) There is significant over-expression in ER+ tumors compared pairwised (n = 9) to normal 
samples (Wilcoxon signed rank test, P = 0.013). No significant difference was found in ER– tumors pairwised compared to normal tissue 
(n = 3) (Wilcoxon signed rank test, P = 0.18).
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Table 1: Clinical and pathological characteristics of our cohort
Overall
n 639
Estrogen receptor status (%) Neg 117 (26.8) (*20.7)
Pos 319 (73.2) (*56.4)
Unknown 130 (*22.9)
Progesteron receptor status (%) Neg 198 (45.4) (*35)
Pos 238 (54.6) (*42)
Unknown 130 (*23)
HER2 status (%) Neg 159 (61.6) (*28.1)
Pos 99 (38.4) (*17.5)
Unknown 308 (*54.4)
Ki67 status (%) Neg 106 (42.7) (*18.7)
Pos 142 (57.3) (*25.1)
Unknown 318 (*56.2)
Nodal Metastases (%) No 31 (47.7) (*5.5)
Yes 34 (52.3) (*6)
Unknown 501 (*88.5)
Year of diagnosis (median [IQR]) 1992.00 [1989.00, 1995.00]
Tumor size in mm (median [IQR]) 22.00 [15.00, 33.00]
Grade (%) 1 11 (11.6) (*1.9)
2 40 (42.1) (*7.1)
3 41 (43.2) (*7.2)
Other 3 (3.2) (*0.5)
Unknown 471 (*83.3)
TNM Stage (%) I 13 (20.3) (*2.3)
IIa 20 (31.2) (*3.5)
IIb 13 (20.3) (*2.3)
IIIa 9 (14.1) (*1.6)
IIIb 6 (9.4) (*1.1)
IV 3 (4.7) (*0.53)
Unknown 502 (*88.7)
Age of diagnosis (median [IQR])  56.00 [46.00, 66.00]
Sampletype (%) Normal 73 (*11.4)
Tumor 566 (*88.6)
Subtype (%) 5NP 7 (3.5) (*1.2)
Basal-like 37 (18.6) (*6.5)
HER2 15 (7.5) (*2.7)
LumA 74 (37.2) (*13.1)
LumB 66 (33.2) (*11.7)
Unknown 367 (*64.8)
Percentages are in brackets of known val 1.
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There was no statistically significant difference in 
miR-190b methylation between breast cancer subtypes in 
BRCA2999del5 mutation carriers (Figure 7) (Kruskal–Wallis 
test, P = 0.383 followed by Dunn‘s multiple comparison).
Breast cancer specific survival and miR-190b
To determine whether miR-190b methylation status 
has prognostic value, we carried out survival analysis 
using a multivariate Cox proportional hazards regression 
for breast cancer specific survival over time. Maximum 
follow-up was approximately 43 years with a mean 
follow-up of 13 years. Breast cancer specific survival 
times did not differ in ER+ tumors with respect to miR-
190b hypo-methylation (HR = 1.35, 95% CI 0.95-1.93, 
P = 0.092) (Figure 8A). After dividing the ER+ cohort 
into subtypes (LumA and LumB) we observed that 
LumA patients showed significantly better survival with 
low methylation (HR = 0.29, 95% CI 0.09-0.91, P = 
0.034) (Figure 8B). There was no statistically significant 
difference in LumB (HR = 1.71, 95% CI 0.76-3.86, P = 
0.194) (Figure 8C) though a trend of poorer breast cancer 
specific survival in hypo-methylated patients could be 
seen. Overall survival analysis of miR-190b expression 
from The Cancer Genome Atlas (TCGA) confirms our 
findings as overall ER+ and LumB tumors do not show 
a statistically significant difference in high versus low 
expression, while LumA does (Supplementary Figure 4).
These results indicate that low miR-190b 
methylation may be protective for individuals of subtype 
Table 2: MiR-190b hypomethylation status according to BRCA2 mutation status in ER+ tumors
MiR-190b non hypomethylation (%) MiR-190b hypomethylation (< 20%)
BRCA2999del5 carriers 26 (81.3%) 6 (18.7%)
WT 173 (62.7%) 103 (37.3%)
P = 0.038, Χ2 = 4.32
Figure 3: MiR-190b expression in breast cancer subtypes. There is a significant elevation in expression within the subtypes 
defined as ER+ (lumA (n = 8) and lumB (n = 18)), compared to ER– subtypes (Basal-like (n = 11) and 5NP (n = 3)) (Kruskal–Wallis, P 
= 1.0e–04). Furthermore, lumA significantly over-expresses MiR-190b compared to lumB. *< 0.05, **< 0.001, ***< 0.0001.
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Figure 4: MiR-190b‘s methylation status by sample type, breast cancer subtype and expression. (A) Overall tumor miR-
190b methylation (n = 514) is significantly lower comparing to normal tissue (n = 72) (Wilcoxon rank sum test, P = 1.18e–04). (B) ER+ 
breast tumors (n = 309) have significantly lower miR-190b methylation status compared to ER– tumors (n = 113) and normal tissue (n = 72) 
(Wilcoxon signed rank test, P = 9.70e–10). (C) Expression status of miR-190b is negatively correlated with it‘s methylation status in breast 
tumors (Spearman’s rho = –0.62, P = 1.83e–06) ***< 0.0001.
Figure 5: MiR-190b methylation in breast cancer subtypes. The ER+ breast cancer subtypes LumA (n = 70) and lumB (n = 61) 
have significantly lower miR-190b methylation comparing to the ER– subtypes HER2 (n = 15), Basal-like (n = 32) and 5NP (n = 7) 
(Kruskal–Wallis test, P = 1.19e–05 followed by Dunn‘s multiple comparison, **< 0.001, ***< 0.0001).
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Figure 6: MiR-190b methylation and proportions of BRCA2-wild-type to mutant allele in BRCA999del5 carrier tumors. 
BRCA2 proportion of 0.5 indicates 1:1 proportions of wt-BRCA2 and 999del5 alleles, values under 0.5 suggest loss of wt-BRCA2. The 
proportions are positively correlated with miR-190b methylation (Multivariate linear regression corrected for ER status, age at diagnosis 
and year of diagnosis, P = 0.008, R2 = 0.45, n = 23).
Figure 7: MiR-190b methylation by breast cancer subtypes in BRCA2 999del5 carriers. There is no statistically significant 
difference in miR-190b methylation between subtypes in patients with the BRCA2 999del5 founder mutation Basal-like (n = 7), LumA 
(n = 9), LumB (n = 17) (Kruskal–Wallis test, P = 0.383 followed by Dunn‘s multiple comparison).
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LumA. There was no significant difference in survival 
of BRCA2999del5 mutation carriers based on miR-190b 
methylation status, this is likely due to a small sample size 
as a trend can be seen (HR = 0.30, 95% CI 0.39-4.69, P = 
0.469) (Supplementary Figure 5).
We analysed breast cancer specific survival in 
patients diagnosed with ER– tumors and found overall 
poorer survival in individuals with low miR-190b 
methylation (HR = 2.25, 95% CI 1.13-4.46, P = 0.020). 
This result is likely unrelated to miR-190b expression as 
ER– tumors do not show over-expression of miR-190b 
according to Figure 2. Owing to lack of statistical power 
survival analysis for ER– subtypes was not performed 
(HER2, Basal-like, 5NP).
DISCUSSION
We show that miR-190b is collectively over-
expressed and hypo-methylated in ER+ breast derived 
tumors and cell lines, indicating that cellular alterations 
occur in ER+ tumors leading to its upregulation. 
Interestingly, LumA tumors have significantly higher 
miR-190b expression compared to LumB while 
hypo-methylation status remains similar between the 
two subtypes. There may thus be additional factors 
facilitating miR-190b expression after loss of methylation 
within LumA tumors which requires further research. 
Heterogeneity in miR-190b methylation can be detected 
in paired normal and tumor samples, as some tumors have 
an increase in miR-190b methylation. This may be due 
to different developmental factors in tumor formation, 
leading to a drive of methyltransferase activation/
deactivation within tumors. The biological implications 
of alterations within the epigenetic machinery can thus 
be changes in phenotypes that cannot be detected with 
conventional genomic sequencing. As such, loss of miR-
190b methylation leads to occurring overexpression when 
the genetic code remains unchanged.
MiR-190b methylation is relevant for breast cancer 
specific survival in patients with LumA cancers. Although 
miR-190b hypo-methylation was detected in ER– 
tumors, over-expression did not occur. In spite of these 
observations, individuals diagnosed with ER– tumors 
showed worse survival when their tumors exhibited miR-
190b hypo-methylation. This likely due to other causes 
than over-expression of miR-190b. Certain sequence-
specific transcription factors needed for inducing high 
expression levels of miR-190b, possibly involving the 
estrogen-receptor and/or it‘s cofactors, are likely absent 
in ER– tumors.
MiR-190b is located within the first intron of transcript 
222 of Tropomyosin 3 (TPM3) (ENST00000515609) 
(Supplementary Figure 1), a small transcript with poorly 
known function [22]. Intragenic DNA methylation has been 
shown to modulate alternative splicing through MeCP2 
and promoting exon recognition [23]. Hypo-methylated 
introns have also been inversly correlated with higher 
levels of intron retention in mRNA from where it is located 
[24]. Previous studies on the TPM3 gene have shown it to 
be involved in tumorigenesis, migration, and invasion in 
hematopoietic tumors as well as expression of MMP family 
members and EMT-like activators in gliomas [25, 26]. 
Alterations of TPM3 on the protein level due to miR-190b 
hypo-methylation could thus be leading to a more agressive 
phenotype in ER– tumors as data from TCGA shows 
no general correlation between miR-190b and changes 
in TPM3 expression (Data not shown) [27–29]. TPM3 
expression in TCGA remains similar between subtypes 
(Data not shown). Our speculations are thus that TPM3 
expression regulation may be carried out similarly, yet fine-
tuned based on subtype, leading to the abovementioned 
changes being found in one but not the other.
Subtype specific survival analysis performed on 
LumA and LumB patients suggests that miR-190b is 
over-expressed in hypo-methylated ER+ breast tumors, 
though only leading to a more favourable prognosis in 
Figure 8: Breast cancer-specific survival by ER status and subtypes by miR-190b methylation status. Cutoff of high and 
low methylation was set at 20%. (A) ER+ breast cancer patients (HR = 1.35, 95% CI 0.95-1.93, P = 0.092). (B) LumA breast cancer patients 
(HR = 0.29, 95% CI 0.09-0.91, P = 0.034). (C) LumB breast cancer patients (HR = 1.71, 95% CI 0.76-3.86, P = 0.194) . All analysis are 
corrected for age at diagnosis, year of diagnosis and BRCA2 mutation status.
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LumA patients (Figure 9). This may be due to targetting 
of oncogenes or oncogenic co-factors. We subsetted our 
cohort to look into any differences in clinical parameters 
between hypo-methylated LumA tumors and LumB 
tumors but did not detect any difference between them. 
We furthermore looked into clinical parameters comparing 
hypo- and methylated (>20%) samples within LumA and 
LumB tumors separately. That, as well, did not lead to any 
further findings.
MiR-190b hypo-methylation was less frequent in 
BRCA2999del5 carrier tumors. Results showing BRCA2 loss 
of heterozygosity in BRCA2999del5 tumors with decreasing 
miR-190b methylation lead us to believe that different 
developmental events due to the mutation may be 
occuring compared to non-mutated tumors. Data from 
TCGA showed no correlation between miR-190b and 
BRCA2 expression on either the mRNA or protein level 
of BRCA2 (Data not shown). With regard to survival, we 
did not see a statistical difference in breast cancer specific 
survival in the patients with BRCA2999del5 mutation due 
to lack of power. It is worth noting that some results, 
specifically when looking into the BRCA2999del5, are based 
on few values. Nonetheless, a trend of worse survival 
was seen in individuals with low miR-190b methylation 
as was observed in patients with ER– and LumB tumors 
(data not shown). Unsurprisingly, 24 of the 34 tumors of 
known subtypes in BRCA2999del5 carriers were LumB and 
Basal-like. Loss of BRCA2 has been linked to increased 
sensitivity to DNA damaging chemotherapeutic agents, 
due to loss of homologus recombination DNA repair 
[30]. Previous assumptions were that most tumors from 
BRCA2 germline mutation carriers had locus-specific 
LOH [31]. Recent studies have however shown otherwise, 
demonstrating that up to roughly 50% of tumors associated 
with BRCA2 germline mutations lack locus-specific LOH 
[32]. Investigating miR-190b with regard to BRCA2 LOH 
in mutation carriers may thus be biologically relevant 
when researching this phenotype. Common miRNA 
target predictions show that direct miR-190b targetting 
of BRCA2 is unlikely, and further research is needed to 
evaluate the abovementioned associations.
Roughly 70% of all breast cancers are diagnosed 
as ER+, which can also be seen in our patient group. 
35% of our ER+ samples are miR-190b hypo-methylated 
indicating high prevalence of this trait. These events may 
be suggestive of early breast cancer development towards 
ER positivity. Early diagnosis is an important factor for 
improved prognosis, and as previously mentioned, ER+ 
tumors are most commonly treated using agents inhibiting 
the estrogen receptor or hormone level [33]. MiR-190b 
Figure 9: Graphical summary of miR-190b methylation and expression in different breast cancer subtypes and prognosis.
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is thus an interesting potential tool for investigating 
developmental aspects regarding ER+ tumors. Additional 
research of miR-190b hypo-methylated and miR-190b 
methylated tumors of the same subtype are key to 
understanding potential targettable factors within these 
subgroups. Transcriptional differences between LumA and 
LumB tumors are particularly intriguing and may lead to 
further characterization of ER+ subtypes.
MATERIALS AND METHODS
Patient groups
The group we used in this study was derived from 
a sample collection previously screened for the Icelandic 
founder BRCA2999del5 germ line mutation [34]. DNA samples 
were available from 549 primary invasive breast tumors, of 
which 62 were derived from BRCA2999del5 carriers. 96 tumor 
RNA samples were available, of which 67 were paired with 
available DNA. 26 of RNA samples came from BRCA2999del5 
carriers, of those, 23 were paired with DNA. 13 RNA 
samples of normal breast tissue, pairing with tumors, were 
available. 71 DNA samples of normal breast tissue were 
available, of which 13 samples were paired with tumors. 
All tumor samples were examined by a pathologist at the 
Department of Pathology Landspitali-University Hospital, 
Iceland. DNA was isolated from freshly frozen tumors by 
phenol-chloroform/proteinase K extraction or, when freshly 
frozen tumors were not available, from formalin-fixed and 
paraffin embedded tumors by xylene-deparaffinization 
and lysis/proteinase K digestion. Normal breast tissues 
were acquired from a distal location of the cancer tissue, 
deriving from the same individuals in our cohort at the time 
of surgery (n = 71). A total of 16 breast derived cell lines 
were used in the study (Supplementary Table 1).
Patient data was provided by the Icelandic Cancer 
Registry [35] as of January 2018, in collaboration with 
pathologists at the Department of Pathology Landspitali-
University Hospital, Iceland. Clinical staging was according 
to the TNM system (tumor size and nodal status), while 
histological grade was assessed by the Nottingham system. 
The study was carried out in compliance with permission from 
the Icelandic Data Protection Commission (2006050307) and 
Bioethics Committee (VSNb2006050001/03-16).
Cell culture
The cell lines used in this study were obtained 
from the American Type Culture Collection (ATCC). The 
cells were cultured in DMEM (CAMA-1, MDAMB-468, 
MCF-7, MCF-10A, MDAMB-231 and SKBr-3), RPMI 
(HCC-38, Bt-474, HCC1937, HCC1428, HCC1500, 
T-47D, ZR-75-1) or Leibovitz’s L-15 (MDA-MB-435, 
MDA-MB-436, MDA-MB-134-VI) with added 10% 
serum (+penicillin/streptomycin) and other supplements 
according to ATCC guidelines.
DNA methylation analysis by pyrosequencing
PyroMark Q24 pyrosequencing instrument was 
used to analyse information on DNA methylation for the 
candidate promoter region of miR-190b. The first CpG, 
166 bases, upstream from miR-190b’s stem-loop sequence 
was analysed (Supplementary Figure 1). We made use of 
Qiagen’s Pyromark Assay Design 2.0 to design primer 
sequences for the analysis.
Bisulfite conversion of the DNA samples was 
carried out using the EZ DNA methylation-gold kit 
(Zymo Research). Pre-PCR amplification of our 
sequence of interest was carried out by using Hot-Start 
polymerase (Immolase, Bioline) in a Veriti (Applied 
Biosystems) thermocycler. The target was amplified 
using forward primer 5′-GGAGAGTTATTTTTTTG 
AGGAAGGGTATTG-′3 and reverse primer 5′-(Btn)
ACCCTACCAAATATTCTTCCTAATTTA-′3 with a PCR 
reaction mixture consisting of: 14,5 µl DNase/RNase-free 
water, 0,5 µl each of forward and reverse primer (10 µM), 
0,8 µl dNTP (100 µM), 1,1 µl MgCl2, 2 µl 10xbuffer, 0.1 
µl Immolase DNA Polymerase, 0,5 µl bisulfite converted 
DNA. The reaction cycle consisted of denaturation at 
95°C for 10 min, 50 cycles of amplification at 95°C for 
30 sec, 56°C for 30 sec and 72°C for 30 sec, and cycle 
completion with extension at 72°C for 10 min. The target 
PCR product was then sequenced by synthesis using 
sequencing PyroMark Q24 reagents and sequencing 
primer 5′-TTTTAAGATAGTTAGTTTTTGTTTA-′3.
The signal data derived from PyroMark Q24 
pyrosequencing of CpG sites, the incorporation of T and 
C, are analysed by Qiagen´s PyroMark Q24 software 
using an in-built CpG methylation analysis feature. The 
output reflects the degree of CpG methylation in percent 
values, from 0 to 100% methylation.
TaqMan miR-190b quantitative PCR in breast 
cancer samples and breast derived cell lines
RNA samples were isolated from freshly frozen 
tumors using Trizol reagent (ThermoFisher). Additionally, 
RNA samples derived from simultaneous RNA/DNA 
isolation by the AllPrep DNA/RNA/miRNA universal Kit 
(Qiagen) method were also included in the cohort. Total 
RNA concentration was quantified by using NanoDrop™ 
One/OneC Microvolume UV-Vis Spectrophotometer 
(ThermoFisher). In total, 77 (62 tumors and 15 normal 
breast tissues) RNA samples were available for expression 
analysis of which 62 samples had corresponding DNA for 
methylation analysis.
MiRNA expression levels were measured by 
quantitative RT-qPCR using FAM labelled pre-designed 
and pre-optimized TaqMan Advanced miRNA Assay 
(Applied Biosystems, cat: A25576). Using TaqMan 
Advanced miRNA cDNA synthesis kit (cat: A28007), the 
RNA samples from patients were reverse transcribed in 
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a 10 ng concentration in a total final volume of 30 µl. 
Each step of cDNA synthesis was carried out as described 
in the manufacture protocol. Subsequently, 5 µl of the 
resulting cDNA was pre-amplified in a final volume of 
50 µl as detailed in the protocol, following the described 
cycling mode. Prior to performing the RT-PCR reactions, 
efficiency analysis was implemented in a 3x fold cDNA 
dilution series of 8 dilutions, starting from undiluted 
sample, to set a cycle range for which the samples should 
not exceed and guarantee reaction efficiency. RT-PCR 
reaction mix ratios were prepared according to protocol 
to a final volume of 5 µl. Each reaction contained: 2,5 µl 
2x Fast Advanced Master Mix, 0,25 µl TaqMan 
Advanced miRNA Assay (20x), 1 µl RNase-free water, 
1,25 µl cDNA in a dilution range within efficiency 
curve limits. BioRad CFX384 Touch™ Real-Time PCR 
Detection System was used, in 384 well plate format, 
the reaction cycle was as follows: denaturation at 95°C 
for 20 sec, 40 cycle amplification at 95°C for 1 sec and 
59°C for 20 sec. Amplification curves were linear for 
all samples and ranged within 90–110% efficiency. 
Each sample was repeated three times in triplicate with 
repetitions of samples exceeding standard deviation 
0,5 per run. To normalize expression levels, miR-190b 
expression was measured relative to miR-425 and miR-
423. Sample dilution was fixed between test and control 
genes. Negative control was added to each reaction run. 
Relative gene expression was calculated using the formula 
2^(-1*(Average test gene expression- Average control gene 
expression)). When combining reference genes for miR-
190b we used the geometric mean between expression 
outcomes of the controls. Threshold cycle levels were 
fixed between each run within the exponential phase 
of the amplification curves. The Cq upper limit was set 
to 36 where Cq values equal to or greater than that was 
considered as not expressed.
TMA (tissue microarray) expression analysis
Tissue microarrays (TMAs) were previously 
constructed and analysed for ER (1D5, DAKO), PR (PgR 
636,DAKO), HER-2 (HercepTest Kit, DAKO) and Ki67 
(MIB1, DAKO) by immunohisochemisty (IHC) [36, 37]. 
ER and PR negativity were defined where staining was 
seen in less than 1% of the tumor cells. HER-2 was 
defined as positive only where intense membranous 
staining was seen, following guidelines provided by the 
antibody manufacturer.
BRCA2 allele-specific quantitative PCR
TaqMan BRCA2 allele-specific quantitative 
PCR was previously performed and analysed [12]. 
Proportions of BRCA2 wild type (wt) relative to 999del5 
BRCA2 mutated alleles were quantitatively measured by 
TaqMan qPCR (7500 Realtime OCR system, Applied 
Biosystems). A single BRCA2-specific minor groove-
binding probe (MGB-probe) 5′-end labelled with FAM 
and a nonfluorescent quencher (NFQ) at the 3′-end, a 
single BRCA2-specific forward primer, and two allele-
specific reverse primers were used: Forward primer: 
5′-CATGATGAAAGTCGTAAGAAA-3′, Reverse primer 
(mut): 5′-CATGACTTGCAGCTTCTCTTTGTG-3′, Reverse 
primer (wt): 5′-CATGACTTGCAGCTTCTCTTTGAT-3′, 
TaqMan-MGB probe: 5′-TTTATCGCTTCTGTGACA-3′.
Statistics
To compare methylation status between groups 
we used Wilcoxon’s rank sum test for independent 
samples, Wilcoxon’s signed rank test for paired samples, 
and non-parametric Kruskal–Wallis with post-hoc 
analysis using Dunn‘s multiple groups comparison [38]. 
Benjamini Hochberg method for false discovery rate 
was used for multiple comparisons correction. To adjust 
for confounding factors between clinical variables that 
resulted significant we used multivariate linear regression 
for modelling the relationship between methylation 
status and given clinical features. We divided miR-
190b methylation outcomes into quartiles resulting in 4 
groups of methylation status ranging from low to high. 
We performed chi-square test for independence between 
methylation status and clinical features. Spearman’s 
non-parametric correlation analysis was performed to 
determine the association between methylation status and 
gene expression. Kaplan–Meier method was applied to 
generate survival curves. Relative hazards were estimated 
in multivariate analyses using the Cox proportional 
hazards model, adjusting for potential confounding factors 
such as ER status, year of diagnosis and age at diagnosis 
[39, 40]. Breast cancer-specific survival is defined as time 
from diagnosis to end of follow-up or death. Survival 
analyses were performed using Survival package in R. 
Patients who died of other causes than breast cancer were 
censored at date of death. The cut off for defining high 
vs low methylation status was set at 20% methylation. 
Cut off was determined at the lower quartile of tumor 
methylation status (19.29%) and rounded up to 20%. 
Follow-up was until January 1st, 2018. Statistical analysis 
was carried out using R program [41] and packages [42–
44]. Generation of Supplementary Figure 1 was carried 
out using Bioconductor packages Gviz, Genomic Ranges 
and biomaRt [45–47].
CONCLUSIONS
We have demonstrated that miR-190b hypo-
methylation events occur in ER+ positive breast cancers 
and are associated with increased breast cancer specific 
survival in LumA patients. MiR-190b‘s association with 
favorable survival in LumA patients suggests that miR-
190b has an active role in these tumors, indicating that 
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there might be transcriptional differences within the ER+ 
subtypes that are yet to be identified as clinically relevant. 
The high prevalence of miR-190 hypo-methylation in 
ER+ breast tumors indicates early onset occurences of 
miR-190b activation, leading us to assume miR-190b 
may have a role in fine-tuning developmental pathways 
in tumorigenesis. We have shown that reduced miR-
190b methylation correlates with locus specific LOH 
in BRCA2999del5 mutation carriers. Less frequent hypo-
methylation in carriers indicates developmental drive 
away from miR-190b hypo-methylation and thus 
restricting over-expression. Further research on miR-190b 
is needed to identify its target genes. Such identification 
may be a useful tool in recognizing relevant biological and 
developmental pathways in breast cancer.
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